Orforglipron, an oral non‐peptide glucagon‐like peptide‐1 receptor agonist, improves markers of β‐cell function and insulin sensitivity in type 2 diabetes

Ähnliche Einträge

• A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy
  von: Filip K. Knop, et al.
  Veröffentlicht: (2024)
• Risks of peri‐ and postoperative complications with glucagon‐like peptide‐1 receptor agonists
  von: David C. Klonoff, et al.
  Veröffentlicht: (2024)
• Use of continuous glucose monitoring when initiating glucagon‐like peptide ‐ 1 receptor agonist therapy in insulin‐treated diabetes
  von: Irl B. Hirsch, et al.
  Veröffentlicht: (2024)
• Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?
  von: Darren Lau, et al.
  Veröffentlicht: (2024)
• Comparative effectiveness of insulin glargine, glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter‐2 inhibitors in veterans with type 2 diabetes
  von: Jincheng Shen, et al.
  Veröffentlicht: (2025)